Compare Ishares Msci Brazil ETF (EWZ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs TG Therapeutics Inc — how do they compare? Ishares Msci Brazil ETF trades at $35.34, while TG Therapeutics Inc trades at $54.85 (market cap $8.64B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, Ishares Msci Brazil ETF nearer its low. Which is the better fit depends on your goals.
| EWZ | TGTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $41.75 | $59.06 |
52-Week Low | $26.52 | $26.39 |
Market Cap | — | $8.64B |
Enterprise Value | — | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $35.33, down 1.94% on the day, yet maintains a bullish technical signal with strong moving average support. The ETF has gained approximately 11% year-to-date, driven by Brazil's monetary easing cycle and commodity strength. Recent news highlights Brazil's economic initiatives and the ETF's exposure to Latin America's equity rally, though key financial ratios like P/E and P/B are not provided in the snapshot.
The outlook for EWZ is cautiously optimistic, with potential upside from Brazil's rate cuts and commodity tailwinds, but risks include economic volatility and reliance on key holdings like Petrobras and Vale. Investors should weigh the concentrated exposure and external factors affecting emerging markets.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
